Tiziana upbeat on latest Milciclib analysis

Tiziana Life Sciences

58.50p

16:35 20/10/21

8.33%

4.50p

Clinical stage biotechnology company Tiziana Life Sciences announced on Friday that the independent data monitor committee (IDMC) has completed interim analysis of the safety and pharmacokinetic data from the first six patients in the Phase 2a trial of ‘Milciclib’.